1205 GMT - AstraZeneca's interest in acquiring Rhythm Pharmaceuticals shouldn't come as a surprise, as it would represent a replay--at a smaller scale--of its purchase of Alexion, Jefferies analysts say. The Wall Street Journal reported on Wednesday that AstraZeneca made a roughly $10 billion offer to buy Rhythm. "Where this approach got to is unclear, but in essence looking for rare disease assets that fit [AstraZeneca's] existing footprint is entirely sensible in our view," Jefferies says. The U.K. drugmaker doesn't need external help to reach its $80 billion 2030 revenue target, but adding assets that offer growth potential isn't a bad idea, the analysts say. AstraZeneca shares rise 0.2%, and Rhythm closed 28% higher on Wednesday.
Comments